Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Conditions
Interventions
Placebo
GSK2330672
Locations
66
United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Novi, Michigan, United States
GSK Investigational Site
Manhasset, New Jersey, United States
GSK Investigational Site
New York, New York, United States
Start Date
January 11, 2017
Primary Completion Date
April 15, 2020
Completion Date
April 15, 2020
Last Updated
May 4, 2021
NCT07185919
NCT07191704
NCT07293897
NCT06049680
NCT06778174
NCT03930810
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions